RUNX1T1 and acute myeloid leukemia: Moreover, there was a trend toward a higher CR rate after one cycle in the DAV group than in the DA group in patients with AML‐bearing KMT2A rearrangements (100% vs 33.3%, p = 0.061), FLT3‐ITD mutations (89.5% vs 61.5%, p = 0.091), and RUNX1::RUNX1T1 (100% vs 69.2%, p = 0.096).